The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. This year’s metric has recorded a Price decrease of -12.02%. However, over the past six months, we’ve seen a stronger performance of -10.58%. The price of RCUS leaped by -8.13% over the last 30 days. And in the last five days, it has surged by 4.38%.
The market performance of Arcus Biosciences Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $20.31 on 02/27/24, while the lowest value for the same duration was $11.55 on 02/12/25.
52-week price history of RCUS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Arcus Biosciences Inc’s current trading price is -35.50% away from its 52-week high, while its distance from the 52-week low is 13.42%. The stock’s price range during this period has varied between$11.55 and $20.31. The Arcus Biosciences Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.39 million for the day, a figure considerably lower than their average daily volume of 0.65 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Arcus Biosciences Inc (RCUS) has experienced a quarterly decline of -21.88% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.20B and boasts a workforce of 577 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 15.45, with a change in price of -3.38. Similarly, Arcus Biosciences Inc recorded 698,197 in trading volume during the last 100 days, posting a change of -20.51%.
RCUS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for RCUS stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.08.
RCUS Stock Stochastic Average
As of today, Arcus Biosciences Inc’s raw stochastic average for the last 50 days stands at 23.70%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 53.45%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 36.09% and 21.41%, respectively.
